ライフサイエンスコーパス: atherogenic

1 esion molecule-1 (PECAM-1) expression is pro-atherogenic.

2 nhibit insulin-induced p-Tyr911 and its anti-atherogenic actions (p-Akt/eNOS) in endothelial cells.

3 , synthetic LXR agonists still elicited anti-atherogenic activity in the absence of hepatic LXRalpha,

4 en changes in CaI and on-treatment levels of atherogenic and antiatherogenic lipoproteins, and C-reac

5 es (cART) are clearly beneficial, but can be atherogenic and could increase stroke risk.

6 eflects the significant lifestyle effects on atherogenic and diabetogenic fat depots.

7 ve pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines.

8 These cells exhibit a persistent atherogenic and inflammatory phenotype even after cultur

9 ng the mechanisms whereby statins reduce the atherogenic and inflammatory phenotype resulting from a

10 ream products, and related genes involved in atherogenic and inflammatory processes in vivo in humans

11 use some experimental studies have suggested atherogenic and lipotoxicity effects of long-chain and v

12 In vivo validation of these pro-atherogenic and osteogenic genes also demonstrates a bro

13 gh plasmatic levels of pro-inflammatory, pro-atherogenic and pro-thrombotic adipokines.

14 The atherogenic and thrombogenic indexes (AI and TI, respect

15 licit a pro-inflammatory cascade known to be atherogenic and to precipitate acute ischemic events.

16 .36+/-6.76%) which led to low omega6/omega3, atherogenic, and thrombogenic index.

17 rmation in response to vascular injury in an atherogenic animal model and explored the molecular mech

18 context of a healthy dietary pattern reduced atherogenic apo C-III-containing LDL and its precursor,

19 apies aiming to reduce circulating levels of atherogenic apoB lipoproteins.

20 n of VLDL secretion reduces plasma levels of atherogenic apolipoprotein B (apoB) lipoproteins but can

21 lbumin excretion relates to higher levels of atherogenic apolipoprotein B fractions in the nondiabeti

22 Additionally, in a pro-atherogenic background, liver-specific deletion of LXRal

23 Since higher levels of NO confer anti-atherogenic benefit, this study has potential implicatio

24 venous ECs switched its phenotype toward pro-atherogenic by up-regulating the expression of inflammat

25 atients with pediatric psoriasis have a more atherogenic cardiometabolic risk profile, with evidence

26 t increase in free radicals acutely triggers atherogenic changes including inflammation, endothelial

27 Atherogenic characteristics of MG(min)-LDL were characte

28 Within sex and diabetes strata, a more atherogenic cholesterol distribution by insulin resistan

29 ins a target of interest because of its anti-atherogenic, cholesterol removal, and anti-inflammatory

30 ptor (LDLR) plays a pivotal role in clearing atherogenic circulating low-density lipoprotein (LDL) ch

31 nhibitory effect on intestinal production of atherogenic CM particles.

32 These findings suggest that atherogenic conditions critically regulate platelet CD36

33 Interestingly, HDL from Hp(-/-) mice under atherogenic conditions does not accumulate Hb and is ant

34 s an important effector molecule integrating atherogenic conditions to direct inflammatory cell entry

35 CD4(+) T-cell responses remain intact under atherogenic conditions.

36 ssified into eight groups: a normal control, atherogenic control and six other experimental groups (f

37 vide key signals for mDC differentiation and atherogenic conversion.

38 contribute to T cells re-activation and pro-atherogenic cytokine production.

39 The anti-atherogenic cytokine TGF-beta inhibits macrophage foam c

40 release of interleukin-1beta and -18, potent atherogenic cytokines.

41 nthesized H2S protects vascular tissues from atherogenic damage by reducing vessel intimal proliferat

42 0.5% kcal from fat) (fructose group, n = 9), atherogenic diet (20% kcal from fructose and 46% kcal fr

43 therogenic diet group, n = 13), and modified atherogenic diet (different source of fat and higher pro

44 mice were fed with either a high-cholesterol atherogenic diet (HCD) or matching normal diet (ND), res

45 1 transgenic mice (AGER1-tg) subjected to an atherogenic diet and arterial wire-injury.

46 atherosclerosis was induced in 18 rabbits by atherogenic diet and double balloon endothelial denudati

47 ression of vascular damage in response to an atherogenic diet by quantifying the in vivo accumulation

48 nd tempers chronic inflammatory responses to atherogenic diet by restraining proinflammatory signalin

49 To do this, DKO mice were first fed an atherogenic diet containing 0.1% cholesterol, 10% fat fo

50 n rats as well as rabbits, fed on normal and atherogenic diet containing 10% of SL1 and SL2 (experime

51 Apo E-KO mice were fed with an atherogenic diet containing 2% (w/w) PS-DHA for 7 weeks.

52 ild-type and heterozygous counterparts on an atherogenic diet despite having lower levels of apolipop

53 Ossabaw pigs fed a modified atherogenic diet develop severe metabolic syndrome and a

54 CSE-knockout mice fed with atherogenic diet developed early fatty streak lesions in

55 iac, hepatic and renal antioxidant status of atherogenic diet fed hamsters.

56 oprotein E-deficient (apoE(-/-)) mice fed an atherogenic diet for 12 weeks.

57 ide transfer protein gene, were placed on an atherogenic diet for 16 weeks, then either made diabetic

58 All mice then were fed an atherogenic diet for 16 weeks.

59 Reversa mice were fed an atherogenic diet for 16 weeks.

60 The atherogenic diet group had metabolic syndrome and abnorm

61 2% cholesterol and 0.7% cholate by weight) (atherogenic diet group, n = 13), and modified atherogeni

62 oprotein E-deficient (ApoE(-/-)) mice fed an atherogenic diet highlighted DC efficacy in effector T-c

63 Atherogenic diet induced a significant (P<0.001) increas

64 ssess an antioxidant protective role against atherogenic diet induced oxidative stress in cardiac, he

65 partly contribute to the inhibitory role of atherogenic diet on lung tumorigenesis.

66 ificantly inhibited the alteration effect of atherogenic diet on the lipid profile and antioxidant en

67 ant administration of allosamidin and fed an atherogenic diet showed aggravated atherosclerotic lesio

68 ntrol and six other experimental groups (fed atherogenic diet supplemented with different doses of P.

69 /+) littermates, followed by feeding them an atherogenic diet to produce atherosclerosis.

70 When fed an atherogenic diet, MAKO/LDLRKO mice displayed exacerbated

71 streptozotocin-induced diabetes consuming an atherogenic diet, without changes in gross glomerular mo

72 Consistently, high cholesterol atherogenic diet-challenged Sort1 knock-out mice showed

73 ces or prevents vascular disease, we treated atherogenic diet-fed ldlr(-/-) mice with recombinant ost

74 nd fatty acid metabolism in high cholesterol atherogenic diet-fed mice.

75 etes, obesity, a sedentary lifestyle, and an atherogenic diet.

76 culating proatherogenic cells in mice fed an atherogenic diet.

77 mice fed either a standard rodent chow or an atherogenic diet.

78 cteristics of autoimmunity in response to an atherogenic diet.

79 G-LDL or in isolated aortae from mice fed an atherogenic diet.

80 tery and abdominal aorta of 7 rabbits fed an atherogenic diet.

81 h muscle cell content after 8 or 16 weeks of atherogenic diet.

82 tery and abdominal aorta of 7 rabbits fed an atherogenic diet.

83 ty lipoprotein receptor Ldlr(-/-) mice on an atherogenic diet.

84 wine by 6 months' feeding of a hypercaloric, atherogenic diet.

85 ressing lipoprotein(a), even in mice not fed atherogenic diets or with overt atherosclerosis.

86 n observed in the arteries of rabbits fed on atherogenic diets was significantly reduced when structu

87 ipids and lipid deposition in animals fed on atherogenic diets.

88 bly in patients with a significant degree of atherogenic dyslipidaemia (high triglycerides and low HD

89 c target for the treatment and prevention of atherogenic dyslipidemia and NAFLD in young insulin resi

90 vo lipogenesis, promoting the development of atherogenic dyslipidemia and NAFLD.

91 rly refined carbohydrate, can exacerbate the atherogenic dyslipidemia associated with insulin resista

92 nonalcoholic fatty liver disease (NAFLD) and atherogenic dyslipidemia associated with the metabolic s

93 hat targeting the central abnormality of the atherogenic dyslipidemia complex, the elevation of trigl

94 e strategy in correcting most aspects of the atherogenic dyslipidemia complex, thereby preventing CVD

95 decades have resulted in an epidemic of the "atherogenic dyslipidemia complex," the main features of

96 s that are known to modify components of the atherogenic dyslipidemia complex.

97 ing new therapeutic strategies to modify the atherogenic dyslipidemia complex.

98 lights the potential importance of targeting atherogenic dyslipidemia in diabetic patients with coron

99 tive for use with individuals exhibiting the atherogenic dyslipidemia of metabolic syndrome.

100 ncreasing burden of CVD risk associated with atherogenic dyslipidemia should primarily emphasize the

101 VD risk, at least in part through effects on atherogenic dyslipidemia, a cluster of traits including

102 d with lower insulin resistance, presence of atherogenic dyslipidemia, and incident diabetes.

103 ue to be a viable treatment option for mixed atherogenic dyslipidemia, and recent reports from clinic

104 e use of niacin as second-line treatment for atherogenic dyslipidemia, with fibrates reserved for tho

105 ated blood pressure, insulin resistance, and atherogenic dyslipidemia.

106 ified molecular explanation for fatty liver, atherogenic dyslipoproteinemia, hyperglycemia, and hence

107 tion, setting the stage for a potential anti-atherogenic effect of this mutation.

108 A number of studies support the anti-atherogenic effect of wine compounds.

109 These direct atherogenic effects are dependent on apoCIII.

110 or 2 (apoER2) results in either pro- or anti-atherogenic effects depending on the ligand.

111 sis that the vasculature is altered by known atherogenic effects of chronic HAART or the prolonged in

112 e/FAS-deficient marrow, consistent with anti-atherogenic effects of LXRalpha in the context of FAS de

113 nt sterol levels and CVD, thereby suggesting atherogenic effects of plant sterols or of cholesterol u

114 he exposure of the entire vasculature to the atherogenic effects of systemic risk factors, atheroscle

115 in mediating one of the most significant pro-atherogenic effects of thrombin.

116 e to its prothrombotic, proinflammatory, and atherogenic effects.

117 nhancer-mediated inflammatory transcription, atherogenic endothelial responses, and atherosclerosis i

118 livery of therapeutics such as siRNAs to pro-atherogenic endothelium.

119 d that shear stress conditions that modulate atherogenic events also regulate Tie1 expression.

120 Carbamylated LDL (cLDL) is a potential atherogenic factor in chronic kidney disease (CKD).

121 ion signaling pathways that are activated by atherogenic factors are poorly defined.

122 At inflammatory sites, where atherogenic factors such as immune complexes and/or path

123 , which can be initiated by physiological or atherogenic factors, is a pivotal process in atherogenes

124 lammatory disease driven by lipids and other atherogenic factors.

125 Individuals with type 1 diabetes have a less atherogenic fasting lipid profile than those without dia

126 actor-2, leading to reduced plaque growth in atherogenic female LDLR(-/-)ApoB-48-deficient mice.

127 rosine kinase Tie1 was evident at regions of atherogenic flow in mature animals.

128 and MBL influence removal and metabolism of atherogenic forms of LDL in the early stages of atherosc

129 C-reactive protein (CRP) binds to atherogenic forms of LDL, but the role of CRP in foam ce

130 oprotein (apo) A-I mediates many of the anti-atherogenic functions attributed to high density lipopro

131 In addition to these indirect atherogenic functions mediated through dyslipidemia, rec

132 ngthen the theory that apoCIII exerts strong atherogenic functions through both indirect and direct m

133 nment can reduce macrophage inflammatory and atherogenic functions through receptor-mediated signalin

134 which induces endothelial expression of pro-atherogenic genes and the subsequent endothelial dysfunc

135 that regulates the expression of an array of atherogenic genes in atherosclerotic lesions.

136 ely regulated expression of IFNgamma-induced atherogenic genes in human EC and SMC by modulating STAT

137 Apolipoprotein A-I (apoA-I) stabilizes anti-atherogenic high density lipoprotein particles (HDL) in

138 After having been fed an atherogenic high-fat (AHF) diet, massive accumulation of

139 Some mice were placed on an atherogenic high-fat diet (16% fat, 41% carbohydrate, an

140 Saturated FA, insulin signals, or an atherogenic high-fat diet can induce CREBH activation in

141 When placed on the atherogenic high-fat diet, the KO mice developed feature

142 ncover A20 as a key physiologic regulator of atherogenic IFNgamma/STAT1 signaling.

143 S100A8/A9, which are atherogenic in mice and are expressed in human atheroscl

144 xcept possibly in patients with an increased atherogenic index (triglyceride : HDL-C ratio), or have

145 d total cholesterol in healthy rats, but not atherogenic index.

146 responses and as a key contributor to early atherogenic inflammation.

147 romatin-dependent signal transduction in the atherogenic inflammatory response, we characterized the

148 Platelet-derived exosomes mediate platelet atherogenic interactions with endothelial cells and mono

149 t here that a cytokine considered to be anti-atherogenic, interleukin-10 (IL10), promotes cholesterol

150 xidative stress are up-regulated by the anti-atherogenic laminar blood flow often seen in straight or

151 ntly blocked the shift in buoyancy from less atherogenic lb-LDL to highly atherogenic sd-LDL, restori

152 atherogenicity that provides a new route to atherogenic LDL and may explain the escalation of cardio

153 zymatically modified LDL (E-LDL), a model of atherogenic LDL to which CRP binds.

154 portant, blacks had a lower concentration of atherogenic LDL with apo C-III at baseline and after stu

155 equently led to the attenuation of the early atherogenic lesion.

156 genes scavenger receptor BI (SR-BI), an anti-atherogenic lipid exchange mediator, activated internali

157 I, -69.64% to -25.35%]; P < 0.001] and other atherogenic lipid fractions, and it reduced all-cause mo

158 pothesized that orally ingested UFP promoted atherogenic lipid metabolites in both the intestine and

159 obiota composition, accompanied by increased atherogenic lipid metabolites.

160 flammation, heightened oxidative stress, and atherogenic lipid profile that may increase women's risk

161 he allergic LDLr(-/-) group despite the more atherogenic lipid profile.

162 tration <20 ng/mL, is correlated with a more atherogenic lipid profile.

163 esterol reduction with regard to a patient's atherogenic lipid profile.

164 e consumption promotes the development of an atherogenic lipid profile.

165 ion as a common molecular mechanism by which atherogenic lipids and amyloid-beta stimulate sterile in

166 ficacy and safety of mipomersen for reducing atherogenic lipids and lipoproteins in patients with hyp

167 At the top of the checklist for reducing atherogenic lipids and recurrent event risk postmyocardi

168 adhesion by binding its receptor CXCR6, and atherogenic lipids are known to stimulate macrophage adh

169 nce in atherosclerotic plaque, we found that atherogenic lipids up-regulated CXCL16 in primary human

170 the balance of proinflammatory mediators and atherogenic lipids.

171 hsCRP, and fibrinogen with little change in atherogenic lipids.

172 nsulin resistance was associated with a more atherogenic lipoprotein cholesterol distribution in all

173 The expected sex-based less atherogenic lipoprotein cholesterol distribution was not

174 lusion: SULF2 is an unexpected suppressor of atherogenic lipoprotein clearance by hepatocytes and an

175 tes most of a 24-h cycle and better captures atherogenic lipoprotein levels.

176 les produced during the oxidation of LDL and atherogenic lipoprotein Lp(a), generating the soluble pr

177 terolemia (FH) are characterized by elevated atherogenic lipoprotein particles, predominantly low-den

178 7-fold increase in plasma cholesterol and an atherogenic lipoprotein profile with increased levels of

179 Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein.

180 ) the association between very low levels of atherogenic lipoproteins achieved with statin therapy an

181 Levels of atherogenic lipoproteins achieved with statin therapy ar

182 enetic associations between plasma levels of atherogenic lipoproteins and 25(OH)D were examined in </

183 ervationally is simply a marker for elevated atherogenic lipoproteins and question a role for vitamin

184 Statins effectively lower atherogenic lipoproteins and result in clinically signif

185 gy to target human ANGPTL3 reduced levels of atherogenic lipoproteins in humans.

186 ion of atherosclerosis and reduced levels of atherogenic lipoproteins in mice.

187 e was associated with decreases in levels of atherogenic lipoproteins in patients receiving treatment

188 Evolocumab markedly reduces atherogenic lipoproteins in patients with type 2 diabete

189 Plasma contains atherogenic lipoproteins of hepatic origin in the fastin

190 Blacks have lower concentrations of atherogenic lipoproteins that contain apo C-III than do

191 ency of TGH in mice lowers plasma lipids and atherogenic lipoproteins without inducing hepatic steato

192 cholesterol and AF extended to several other atherogenic lipoproteins, and these associations are unl

193 )D levels are associated with high levels of atherogenic lipoproteins, but whether these 2 risk facto

194 polipoprotein-B (apoB), the major protein of atherogenic lipoproteins, is regulated through posttrans

195 s, evolocumab decreased the concentration of atherogenic lipoproteins, particularly LDL, by accelerat

196 e, along with serum cholesterol measures and atherogenic lipoproteins.

197 impart anti-inflammatory effects by reducing atherogenic lipoproteins.

198 polipoprotein B, reduces LDL cholesterol and atherogenic lipoproteins.

199 antly increased plasma total cholesterol and atherogenic low-density lipoprotein cholesterol levels i

200 Lipoprotein(a) [Lp(a)] is a highly atherogenic low-density lipoprotein-like particle charac

201 rotective high-density lipoproteins (HDL) to atherogenic low-density lipoproteins (LDL).

202 tin plays a role in regulating the uptake of atherogenic low-density lipoproteins in human hepatocyte

203 nol levels in the cecum, as well as elevated atherogenic lysophosphatidylcholine (LPC 18:1) and lysop

204 , SAA alters vascular proteoglycans in a pro-atherogenic manner via the stimulation of TGF-beta and m

205 synthesis and lipoprotein retention in a pro-atherogenic manner.

206 ders macrophages unable to degrade exogenous atherogenic material and endogenous cargo including dysf

207 To test this potential atherogenic mechanism more specifically, we performed ca

208 ectin provides clues to the inflammatory and atherogenic mechanisms associated with pathological coro

209 -methionine diets elevate plasma Hcy and its atherogenic metabolite Hcy-thiolactone.

210 We found that atherogenic mice (herein referred to as LDb mice) exhibi

211 To inhibit growth of vasa vasorum in atherogenic mice and assess its effect on plaque growth,

212 quely associates with proinflammatory HDL in atherogenic mice and coronary heart disease (CHD) patien

213 Pioglitazone treatment of atherogenic mice prevented this progression of atheroscl

214 Furthermore, when non-atherogenic mice were treated with synthetic LXR agonist

215 ingle miRNA deficiency in diet-induced obese atherogenic mice.

216 ory signaling or by pro-inflammatory and pro-atherogenic microRNAs, miR-155 and miR-33.

217 otentially cardioprotective in patients with atherogenic 'mixed' dyslipidemia.

218 the potential importance of glycation as an atherogenic modification of LDL, factors determining gly

219 F2) is a critical anti-inflammatory and anti-atherogenic molecule in vascular endothelium.

220 declines in total cholesterol (-24.8 mg/dl), atherogenic (non-high-density lipoprotein) cholesterol (

221 Expression of the anti-atherogenic nuclear receptor liver X receptor alpha (LXR

222 DL produced by interaction with CETP had pro-atherogenic or pro-inflammatory properties.

223 nidirectional laminar shear stress (LSS) and atherogenic oscillatory shear stress (OSS).

224 , leading investigators to study the role of atherogenic oxidatively modified lipids (oxylipids).

225 To determine whether atherogenic oxidized phospholipids potentially contribut

226 the combination of low shear stress (SS) and atherogenic oxLDL.

227 mice were fed with either a control chow or atherogenic paigen-type diet for 12 weeks.

228 Among women with low total atherogenic particle burden (apolipoprotein B100 level <

229 oprotein cholesterol (LDL-C) levels or total atherogenic particle burden (apolipoprotein B100) is les

230 ts provide evidence of decreased exposure to atherogenic particles in carriers of the minor SORT1 all

231 isk is more closely related to the number of atherogenic particles than to the total mass of choleste

232 in therapy, on-treatment levels of LDL-C and atherogenic particles were associated with residual risk

233 es a measure of cholesterol contained in all atherogenic particles.

234 ant associations for non-HDL cholesterol and atherogenic particles: apolipoprotein B and ion mobility

235 e (GSK) 3alpha/beta in the activation of pro-atherogenic pathways and the accelerated development of

236 -seq approaches identified activation of pro-atherogenic pathways involving a complex interplay of hi

237 ic reticulum stress in the activation of pro-atherogenic pathways.

238 Our results suggest that tolerance to atherogenic peptides increases regulatory T cells which

239 g values, compared to SS, NASH showed a more atherogenic postprandial lipoprotein profile, an altered

240 with PPAR agonists can reduce the burden of atherogenic postprandial lipoproteins and improve vascul

241 medically important ligands, such as HIV-1, atherogenic postprandial remnant lipoproteins, and molec

242 mellitus (T2DM) impairs hepatic clearance of atherogenic postprandial remnant lipoproteins.

243 mellitus (T2DM) impairs hepatic clearance of atherogenic postprandial triglyceride-rich lipoproteins

244 tial inflammatory response that precedes the atherogenic process by targeting different steps of the

245 ndothelium constitutes an early event of the atherogenic process.

246 reas of low ESS, which exacerbates the local atherogenic process.

247 cess during atherosclerosis, thereby linking atherogenic processes and pathological angiogenesis.

248 otein (apo) C-III in VLDL and LDL stimulates atherogenic processes in vascular cells.

249 rdial infarction (MI) and directly activates atherogenic processes in vascular cells.

250 n genetic factors that facilitate these anti-atherogenic processes remain largely unknown.

251 advances highlight important cell biological atherogenic processes, including mechanotransduction and

252 ment of LDL lipid subfractions toward a less atherogenic profile [decreased small LDL IIIb (-44 +/- 2

253 e during gestation is associated with a more atherogenic profile in adult offspring.

254 emonstrated that miR-155 plays a key role in atherogenic programming of macrophages to sustain and en

255 s study examines whether obesity accelerates atherogenic progression or adverse outcomes after corona

256 KS silencing could selectively suppress the "atherogenic," proliferative phenotype of VSMCs without c

257 ndothelial arginase activity is increased in atherogenic-prone apolipoprotein E-null (ApoE(-/-)) and

258 cardioprotective effects in humans and anti-atherogenic properties in animal models.

259 c adipocytes affects the metabolism and anti-atherogenic properties of high-density lipoproteins (HDL

260 e molecule with insulin-sensitizing and anti-atherogenic properties, suppresses pro-inflammatory gene

261 to the links between structure, function and atherogenic properties.

262 We showed that MIF promotes the atherogenic recruitment of monocytes and T cells through

263 receptors for Ccl5 and Ccl2 are important in atherogenic recruitment of neutrophils and monocytes, we

264 Targeting these pro-atherogenic regions is a potential anti-atherogenic ther

265 ) exposed to disturbed flow condition in pro-atherogenic regions.

266 P = 5.5 x 10(-8)), suggesting that targeting atherogenic remnant cholesterol may reduce cardiovascula

267 hrough their metabolic activity decrease pro-atherogenic remnant lipoproteins in hyperlipidemic mice.

268 owing in part to the accompanying burden of atherogenic remnant particles, small dense low-density l

269 d metalloproteases (ADAMs) and stimulate pro-atherogenic responses, endothelial inflammation and perm

270 olic alterations, promoting inflammatory and atherogenic responses.

271 EM-1) plays a determinant role in macrophage atherogenic responses.

272 provide evidence about benefit of aggressive atherogenic risk factor management.

273 f a cohort with detailed characterization of atherogenic risk factors, including surrogate markers of

274 stprandial response that may result in lower atherogenic risk for these persons.

275 h that NOR1 serves a previously unrecognized atherogenic role in mice by positively regulating monocy

276 These combined results highlight the atherogenic role of MAC and the atheroprotective role of

277 The atherogenic role of terminal complement has long been su

278 To confirm the atherogenic role of this receptor cloned against copper-

279 e results suggest that GSK3alpha plays a pro-atherogenic role, possibly by mediating the effects of e

280 acrophage-targeted uPA overexpression reveal atherogenic roles for both uPA and Plg and are a useful

281 yancy from less atherogenic lb-LDL to highly atherogenic sd-LDL, restoring the percent distribution o

282 es during sleep in absence of concurrent pro-atherogenic settings (i.e., genetic propensity or dietar

283 plays a role in the endothelial response to atherogenic shear stress.

284 tly by gender and, in females, a substantial atherogenic shift overlapping the time of menopausal tra

285 n-3 FA inhibit atherogenic signaling pathways and modulate the phenotyp

286 Elevated triglycerides are a marker of atherogenic small dense LDL, excess baseline and residua

287 Recent studies suggested that the atherogenic state correlates with progression of chronic

288 may reflect heightened inflammatory and pro-atherogenic states of the systemic vasculature.

289 ghtens the sensitivity of the vasculature to atherogenic stimuli.

290 xidized low-density lipoprotein (ox-LDL), an atherogenic stimulus, reduced PIAS3 expression, an effec

291 P released from cultured cells in a model of atherogenic stress.

292 of 0.5 ml each for 30 days, in rats, fed an atherogenic suspension.

293 n margarines should be improved by replacing atherogenic TFA and SFA with beneficial ones, in order t

294 nd apo A-I and, therefore, appear to be less atherogenic than is a low-fat, high-carbohydrate diet.

295 pro-atherogenic regions is a potential anti-atherogenic therapeutic approach, but it has been extrem

296 (ACS) are treated with statins, which reduce atherogenic triglyceride-rich lipoproteins.

297 s, whereas expression of the potentially pro-atherogenic type B scavenger receptor CD36 was decreased

298 originate through the delipidation of larger atherogenic VLDL and large LDL and from direct de novo p

299 uble knockouts (DKOs) and challenged with an atherogenic Western diet.

300 Low-density lipoprotein (LDL) is non-atherogenic, while oxidized LDL (ox-LDL) is critical to